BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...interest in the target. According to BioCentury’s BCIQ database, Innate Pharma Inc. (Euronext:IPH; NASDAQ:IPHA) and CanCure LLC...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...Preclin Ligands CanCure LLC CuraB-10 Antibody MHC class I polypeptide-related sequence A (MICA) / MICB Preclin CanCure LLC...
...Innate Pharma S.A. (Euronext:IPH) IPH4301 Antibody MICA / MICB Preclin Four companies -- Oxford, Innate, CanCure LLC...
...researchers. Only one other company -- CanCure -- has disclosed programs against MICB for cancer. CanCure’s...
BioCentury | Apr 3, 2018
Distillery Therapeutics

Cancer

...domains in combination with other therapies in animal models of melanoma and multiple myeloma (MM). CanCure LLC...
BioCentury | Jun 29, 2017
Product R&D

Drop the MIC

...unexplored ligands for the NK cell receptor NKG2D . Having laid low for four years, CanCure LLC...
...and other abnormal cells, and their low liability for cytokine release syndrome. On May 17, CanCure...
...MICB, and he hopes to have it in Phase I testing by 2019 or 2020. CanCure...
Items per page:
1 - 4 of 4
BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

...interest in the target. According to BioCentury’s BCIQ database, Innate Pharma Inc. (Euronext:IPH; NASDAQ:IPHA) and CanCure LLC...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...Preclin Ligands CanCure LLC CuraB-10 Antibody MHC class I polypeptide-related sequence A (MICA) / MICB Preclin CanCure LLC...
...Innate Pharma S.A. (Euronext:IPH) IPH4301 Antibody MICA / MICB Preclin Four companies -- Oxford, Innate, CanCure LLC...
...researchers. Only one other company -- CanCure -- has disclosed programs against MICB for cancer. CanCure’s...
BioCentury | Apr 3, 2018
Distillery Therapeutics

Cancer

...domains in combination with other therapies in animal models of melanoma and multiple myeloma (MM). CanCure LLC...
BioCentury | Jun 29, 2017
Product R&D

Drop the MIC

...unexplored ligands for the NK cell receptor NKG2D . Having laid low for four years, CanCure LLC...
...and other abnormal cells, and their low liability for cytokine release syndrome. On May 17, CanCure...
...MICB, and he hopes to have it in Phase I testing by 2019 or 2020. CanCure...
Items per page:
1 - 4 of 4